Statement of Principles concerning bronchiectasis No. 60 of 2001

Administered by Department of Veterans' Affairs

Legislation au F2005B01764 Not in force Legislative Instrument

Legislation content

Instrument No.60 of 2001

 

Revocation and Determination

of

Statement of Principles

concerning

 

BRONCHIECTASIS

 

ICD-10-AM CODE: J47

 

Veterans’ Entitlements Act 1986

 

 

1. The Repatriation Medical Authority under subsection 196B(3) of the Veterans’ Entitlements Act 1986 (the Act):

 

(a) revokes Instrument No.36 of 1997; and

 

(b) determines in its place the following Statement of Principles.

 

Kind of injury, disease or death

2. (a) This Statement of Principles is about bronchiectasis and death from bronchiectasis.

 

(b)              For the purposes of this Statement of Principles, bronchiectasisbronchiectasis” means irreversible focal or generalised bronchial dilatation of medium sized airways, attracting ICD code J47.  It does not include congenital bronchiectasis, or bronchiectasis associated with cystic fibrosis, alpha-1-antitrypsin deficiency or other genetic disorders.

 

Basis for determining the factors

3. On the sound medical-scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that bronchiectasis and death from bronchiectasis can be related to relevant service rendered by veterans or members of the Forces.

 

Factors that must be related to service

4. Subject to clause 6, at least one of the factors set out in clause 5 must be related to any relevant service rendered by the person.

 

Factors

5. The factors that must exist before it can be said that, on the balance of probabilities, bronchiectasis or death from bronchiectasis is connected with the circumstances of a person’s relevant service are:

 

(a) suffering from pneumonia before the clinical onset of bronchiectasis, with continual or recurrent respiratory symptoms in the interval between that episode of pneumonia and the clinical onset of bronchiectasis; or

 

(b) suffering from mycobacterial infection of the affected area of the lung before the clinical onset of bronchiectasis; or

 

(c) suffering from sarcoidosis of the lung before the clinical onset of bronchiectasis; or

 

(d) suffering from bronchial obstruction before the clinical onset of bronchiectasis, where the bronchiectasis is distal to that obstruction; or

 

(e)               inhaling toxic gases or fumes within the 90 days before the clinical onset of bronchiectasis; or

 

(f)                inhaling mustard gas before the clinical onset of bronchiectasis; or

 

(g)               aspirating gastric contents, resulting in acute respiratory distress within the 90 days before the clinical onset of bronchiectasis; or

 

(h) suffering from allergic bronchopulmonary aspergillosis at the time of the clinical onset of bronchiectasis; or

 

(j) undergoing a lung or heart-lung transplantation before the clinical onset of bronchiectasis in the transplanted lung; or

 

(k)               having suffered from collapse or fibrosis of the segment of the lung affected by bronchiectasis before the clinical onset of bronchiectasis; or


(m) suffering from pneumonia within the one year before the clinical worsening of bronchiectasis; or

 

(n) suffering from mycobacterial infection of the affected area of the lung before the clinical worsening of bronchiectasis; or

 

(o) suffering from sarcoidosis of the lung before the clinical worsening of bronchiectasis; or

 

(p) suffering from bronchial obstruction before the clinical worsening of bronchiectasis, where the bronchiectasis is distal to that obstruction; or

 

(q)               inhaling toxic gases or fumes within the 90 days before the clinical worsening of bronchiectasis; or

 

(r)                inhaling mustard gas before the clinical worsening of bronchiectasis; or

 

(s) aspirating gastric contents, resulting in acute respiratory distress within the 90 days before the clinical worsening of bronchiectasis; or

 

(t) suffering from allergic bronchopulmonary aspergillosis at the time of the clinical worsening of bronchiectasis; or

 

(u) having suffered from collapse or fibrosis of the segment of the lung affected by bronchiectasis before the clinical worsening of bronchiectasis; or

 

(v)              inability to obtain appropriate clinical management for bronchiectasis.

 

Factors that apply only to material contribution or aggravation

6. Paragraphs 5(m) to 5(v) apply only to material contribution to, or aggravation of, bronchiectasis where the person’s bronchiectasis was suffered or contracted before or during (but not arising out of) the person’s relevant service; paragraph 8(1)(e), 9(1)(e) or 70(5)(d) of the Act refers.

 

Inclusion of Statements of Principles

7. In this Statement of Principles if a relevant factor applies and that factor includes an injury or disease in respect of which there is a Statement of Principles then the factors in that last mentioned Statement of Principles apply in accordance with the terms of that Statement of Principles.

 

Other definitions

8. For the purposes of this Statement of Principles:

 

“acute respiratory distress” means sudden onset of deterioration in respiratory function with symptoms or signs of tachypnoea, cyanosis, dyspnoea, hypoxaemia, or wheezing;

 

“allergic bronchopulmonary aspergillosis” means a condition where patients with pre-existing asthma and eosinophilia (>1000 eosinophils/micro litre) develop immediate wheal-and-flare response to Aspergillus fumigatus, serum precipitins to A fumigatus, elevated serum IgE, fleeting pulmonary infiltrates from bronchial plugging and central bronchiectasis;

 

“inhaling toxic gases or fumes” means inhaling anhydrous ammonia fumes, smoke, oxides of sulphur, chlorine or phosgene, resulting in acute respiratory distress with evidence of pulmonary oedema or evidence of pneumonitis;

 

“bronchial obstruction” means partial or complete blockage of a bronchus;

 

“death from bronchiectasis” in relation to a person includes death from a terminal event or condition that was contributed to by the person’s bronchiectasis;

 

 “ICD-10-AM code” means a number assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, 10th revision, Australian Modification (ICD-10-AM), Second Edition, effective date of 1 July 2000, copyrighted by the National Centre for Classification in Health, Sydney, NSW, and having ISBN 1 86487 271 3;

 

“mycobacterial infection” means infection by mycobacterium tuberculosis or non-tuberculous mycobacteria;

 

“pneumonia” means inflammation of the lung with clinical or radiological evidence of consolidation;

 

“relevant service” means:

 

(a) eligible war service (other than operational service); or

(b) defence service (other than hazardous service);

 

“sarcoidosis” means a chronic, multisystem disorder of unknown cause characterised by an accumulation of T lymphocytes and mononuclear phagocytes, noncaseating epithelioid granulomas, and derangement of the normal tissue architecture in affected organs;

 

“terminal event” means the proximate or ultimate cause of death and includes:

 

(a) pneumonia;

(b) respiratory failure;

(c) cardiac arrest;

(d) circulatory failure; or

(e)              cessation of brain function.

 

Application

9. This Instrument applies to all matters to which section 120B of the Act applies.

 

 

Dated this Fourteenth day of  August  2001

 

 

The Common Seal of the    )

Repatriation Medical Authority   )

was affixed to this instrument  )

in the presence of:    )

KEN DONALD

CHAIRMAN

Overview

The Veterans' Entitlements Act 1986, enacted to provide various benefits and compensation to veterans and their families, was amended through Instrument No.60 of 2001, which revokes and replaces previous instruments concerning bronchiectasis. This legislative instrument, issued by the Repatriation Medical Authority, addresses the problem of establishing a clear connection between bronchiectasis and the service rendered by veterans, aiming to ensure that appropriate medical recognition and benefits are granted. The Repatriation Medical Authority determined, based on available medical-scientific evidence, that it is more probable than not that bronchiectasis and related deaths can be linked to relevant military service. This legislative update aims to clarify the specific factors that must be related to service for a claim to be considered valid, thereby facilitating the provision of necessary support and recognition to affected veterans. The instrument specifically defines bronchiectasis as irreversible focal or generalised bronchial dilatation of medium-sized airways, attracting ICD code J47, while excluding congenital bronchiectasis and cases associated with cystic fibrosis, alpha-1-antitrypsin deficiency, or other genetic disorders. To establish a connection between bronchiectasis and military service, at least one of several specified factors must be related to the service. These factors include previous respiratory infections, exposure to toxic substances, and other medical conditions that precede or worsen the condition. The legislative update also clarifies that certain factors apply only in cases where the bronchiectasis was present before or during service, but not arising out of it. This comprehensive approach aims to ensure that veterans who suffer from bronchiectasis receive the recognition and benefits they are entitled to under the Act.

Scope and Application

This legislative instrument, issued under the Veterans’ Entitlements Act 1986, addresses the revocation and determination of the Statement of Principles concerning bronchiectasis and death from bronchiectasis. Specifically, it revokes Instrument No.36 of 1997 and establishes new criteria for determining the connection between bronchiectasis and service rendered by veterans or members of the Australian Defence Force. The new Statement of Principles delineates the conditions under which bronchiectasis or death from bronchiectasis can be considered related to relevant service, excluding congenital bronchiectasis or cases associated with genetic disorders like cystic fibrosis or alpha-1-antitrypsin deficiency. The instrument outlines specific factors that must exist to establish a connection, such as suffering from pneumonia or inhaling toxic gases before the onset of bronchiectasis, and applies to all matters covered by section 120B of the Act. This legislation thus establishes a clear framework for assessing and potentially compensating veterans who have developed bronchiectasis as a result of their service, with a focus on evidence-based medical-scientific assessments.

Key Provisions

This legislative instrument, under section 196B(3) of the Veterans' Entitlements Act 1986, revokes Instrument No.36 of 1997 and replaces it with a new Statement of Principles concerning bronchiectasis and death from bronchiectasis (sections 1 and 2). The new Statement of Principles outlines the factors that must exist for a veteran or member of the Defence Forces to be considered to have contracted or had their bronchiectasis materially contributed to or aggravated by their service (section 5). These factors include suffering from pneumonia, mycobacterial infection, sarcoidosis, bronchial obstruction, inhaling toxic gases or fumes, aspirating gastric contents, or having a lung or heart-lung transplantation, among others, prior to the onset or worsening of bronchiectasis. It is essential that at least one of these factors must be related to the person's relevant service for a connection to be made (section 4). The obligations under this Act require the Repatriation Medical Authority to consider the medical-scientific evidence available and determine if it is more probable than not that the bronchiectasis or death from bronchiectasis is related to the service rendered by the veteran or member of the Defence Forces (section 3). The authority must also consider whether the factors listed in section 5 apply to the individual's case, and if so, whether any of these factors are related to the person's relevant service. Furthermore, the authority must ensure that if a relevant factor includes an injury or disease with an existing Statement of Principles, the factors in that Statement of Principles apply in accordance with its terms (section 7). There are no specific offences, penalties, or consequences outlined in this legislative instrument for breach. However, failure to comply with the provisions of the Veterans' Entitlements Act 1986 or the determinations made under this Act may result in legal consequences, such as the denial of veterans' entitlements or other related matters. The maximum penalties for offences under the Veterans' Entitlements Act 1986 vary depending on the specific offence and can include fines and/or imprisonment. It is important for parties and entities governed by this Act to adhere to its provisions to avoid any potential legal repercussions.

Legal classification tags

Area of Law
Veterans' Law
Instrument
Legislative Instrument
Concepts
Definitions & Interpretation
Prohibited Conduct
Rights & Protections

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.